{"entity":{"id":"apc","kind":"target","name":"APC","aka":["APC regulator of Wnt signaling pathway","Adenomatous polyposis coli protein","DP2","DP3","DP2.5","PPP1R46"],"tldr":"APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.","summary":"Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state.\n\nCIViC holds 5 clinical evidence items and 0 assertions across 2 variants, naming JW55, G007-LK, Nirogacestat and Regorafenib. Open Targets scores its association with cancer at 0.91 (direct and indirect evidence; datatypes genetic literature 0.79, affected pathway 0.86, literature 1.00, genetic association 0.90, somatic mutation 0.97, animal model 0.88). IntOGen calls it a driver in 43 cohorts (2 activating, 41 loss-of-function), covering Acute Myeloid Leukaemia, Anal Squamous Cell Carcinoma, Cholangiocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma and others. In OnCo, 1 product record names it (Nirogacestat).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:583","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:583"},{"label":"UniProt P25054","url":"https://www.uniprot.org/uniprotkb/P25054/entry"},{"label":"NCBI Gene 324","url":"https://www.ncbi.nlm.nih.gov/gene/324"},{"label":"Ensembl ENSG00000134982","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134982"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["colorectal","gastric","hcc","prostate","esophageal","biliary-tract-cancer","anal","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["nirogacestat"],"companies":[],"institutions":[],"pathways":["colorectal-cancer-signalling","gastric-cancer-signalling","mitotic-spindle-checkpoint","wnt"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 41 cohorts; CIViC holds 5 clinical evidence items on its variants. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"APC","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:583","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:583","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P25054","url":"https://www.uniprot.org/uniprotkb/P25054/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene APC","url":"https://civicdb.org/features/66","note":"5 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Colon Carcinoma, Desmoid Tumour (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000134982","url":"https://platform.opentargets.org/target/ENSG00000134982/associations","note":"association with cancer (MONDO_0004992) 0.91; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.56, colorectal cancer 0.86, gastric cancer 0.81, oesophageal cancer 0.55, hepatocellular carcinoma 0.74, prostate cancer 0.65 (GraphQL API, CC0)"},{"label":"IntOGen APC","url":"https://www.intogen.org/search?gene=APC","note":"driver in 43 cohorts (Act 2, LoF 41); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:583","ensembl":"ENSG00000134982","uniprot":"P25054","entrez":"324","biology":"Tumour suppressor. Promotes rapid degradation of CTNNB1 and participates in Wnt signalling as a negative regulator. APC activity is correlated with its phosphorylation state. Activates the GEF activity of SPATA13 and ARHGEF4. Plays a role in hepatocyte growth factor (HGF)-induced cell migration. Required for MMP9 up-regulation via the JNK signalling pathway in colorectal tumour cells. Location: Cell junction, adherens junction; Cytoplasm, cytoskeleton; Cell projection, lamellipodium; Cell projection, ruffle membrane (UniProt). Locus 5q22.2 (HGNC).","whereFound":["Colorectal cancer: Open Targets association 0.86 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease","Gastric & gastro-oesophageal junction cancer: Open Targets association 0.81 with gastric cancer (MONDO_0001056); IntOGen driver in 6 cohorts (EGC, STAD, STOMACH)","Hepatocellular carcinoma: Open Targets association 0.74 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 2 cohorts (HCC)","Prostate cancer: Open Targets association 0.65 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD, PROSTATE)","Oesophageal cancer: Open Targets association 0.55 with oesophageal cancer (MONDO_0007576); IntOGen driver in 4 cohorts (ESCA, ESCC)","Biliary tract cancer: Open Targets association 0.58 with biliary tract cancer (MONDO_0003060)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/apc/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/"},{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/"}],"pathway":[{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/"},{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/"},{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"},{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/"}]}}